BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer 2020;28:6129-43. [PMID: 32856210 DOI: 10.1007/s00520-020-05707-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Rapoport BL, Cooksley T, Johnson DB, Anderson R. Supportive care for new cancer therapies. Curr Opin Oncol 2021;33:287-94. [PMID: 33756517 DOI: 10.1097/CCO.0000000000000736] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kunogi Y, Tominaga K, Abe K, Kanazawa M, Tanaka T, Watanabe S, Kondo M, Kanamori A, Iijima M, Goda K, Nozawa Y, Ishida K, Irisawa A. Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. Healthcare (Basel) 2021;9:418. [PMID: 33916353 DOI: 10.3390/healthcare9040418] [Reference Citation Analysis]
3 Rizzo A, Mollica V, Santoni M, Massari F. Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. Expert Rev Gastroenterol Hepatol 2021;:1-8. [PMID: 34167420 DOI: 10.1080/17474124.2021.1948328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]